Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 118,932

Document Document Title
WO/2016/115290A1
The present invention provides polypeptides and their variants and derivatives which modulate GABAA receptor function at nanomolar quantities by binding to the α+/β- subunit interface, as well as methods of making and using the same. T...  
WO/2016/114707A8
The present invention relates to derivatives of dehydroabietic acid useful in treatment ofcardiac arrhythmiaor a hyperexcitablity disease, such as epilepsy or pain, by extracellularly acting on the voltage sensitive domain (VSD) to open ...  
WO/2016/115223A1
This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering eltoprazine or a pharmaceutically acceptable acid addition s...  
WO/2016/115382A1
The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering ...  
WO/2016/112875A2
The present invention relates to a diphenyl derivative and uses thereof, the diphenyl derivative having the structure as indicated in formula (I) defined in the description. The uses refer to the uses of the diphenyl derivative, pharmace...  
WO/2016/114386A1
A therapeutic agent for progressive demyelinating immune disease containing, as an active ingredient thereof, a substance for suppressing or inhibiting signal transduction initiated by the PAR1 receptor.  
WO/2016/114655A1
The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pha...  
WO/2016/115054A3
Described herein are compounds that modulate the activity of CRAC channels, methods of making such compounds, pharmaceutical compositions, and medicaments containing such compounds, and methods of using such compounds in the treatment of...  
WO/2016/113802A1
The present invention provides: a furoxan compound having a fluorine atom as a substituent group on the ring structure thereof; and a novel nitric oxide donor using said compound. The present invention is a fluorofuroxan compound represe...  
WO/2016/112768A1
The present invention relates to a benzofuroxan oxide histone deacetylase inhibitor, and a preparation method therefor and uses thereof. The compound has a structure represented by a formula I or I', a tautomer II represented by the form...  
WO/2016/114602A9
Disclosed herein a pharmaceutical composition comprising aprepitant or a pharmaceutically acceptable salt thereof; at least one hydrocarbon derivative selected from among a fatty acid of 14 to 18 carbon atoms, and a fatty alcohol of 14 t...  
WO/2016/115434A1
Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods f...  
WO/2016/113668A1
The invention relates to heterocyclic angiotensin II type 2 (AT2) receptor antagonists of formula (I), and pharmaceutically acceptable salts thereof, ((I) in which all of the variables are as defined in the specification, pharmaceutical ...  
WO/2016/111347A1
Provided is a drug the active ingredient of which is a compound having antagonistic activity against EP4 receptor in the prevention and/or treatment of disease attributed to activation of EP4 receptor. The compound represented by general...  
WO/2016/111285A1
Disclosed are: a medicinal composition, a cosmetic, a food and a drink each comprising a porous ceramic, said porous ceramic being obtained by subjecting a starting material, which contains (1) titanium and (2) at least one member select...  
WO/2016/112382A3
The presently disclosed subject matter provides methods for treating and diagnosing neurological diseases or disorders using intranasal administration of glutamate carboxypeptidase II (GCP-II) inhibitors in a subject. Methods for imaging...  
WO/2016/110216A1
A method for extracting stilbene compounds comprises the following steps: grinding a medicinal material rich in stilbene compounds such as rheum officinale; extracting the medicinal material with a herbal blitzkrieg extractor for one to ...  
WO/2016/110499A1
This disclosure relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof: in which m, p, A, Ar1, Ar2, Ar3, R1, R2, and R3 are defined in the specification. The compounds of formula (I) can be used as CGRP antagon...  
WO/2016/111843A1
Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferriti...  
WO/2016/111357A1
The present invention is directed to the compound (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9- tetrahydrospiro[ß-carboline-4,1'-cyclopropane] represented by the formula. This compound, when compared to conventionally-kno...  
WO/2016/110334A1
The invention relates to the pharmaceutical or non-pharmaceutical use of an effective amount of spirulina and/or of an extract/extracts of spirulina for improving the bioavailability of orally administered curcumin in humans or animals. ...  
WO/2016/112205A1
Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treat...  
WO/2016/112382A2
The presently disclosed subject matter provides methods for treating and diagnosing neurological diseases or disorders using intranasal administration of glutamate carboxypeptidase II (GCP-II) inhibitors in a subject. Methods for imaging...  
WO/2016/110541A1
The present invention relates to selective Histone deacetylase 6 (HDAC6) inhibitors and compositions containing the same. Methods of treating diseases and conditions wherein inhibition of HDAC6 provides a benefit, like a cell proliferati...  
WO/2016/111377A1
The medicinal composition and cosmetic according to the present disclosure each comprise an iPS cell culture supernatant that is obtained by culturing iPS cells. The present disclosure also provides: a method for producing the aforesaid ...  
WO/2016/111378A1
The composition for treating a neurodegenerative disease according to the present disclosure comprises an iPS cell culture supernatant that is obtained by culturing iPS cells. The present disclosure also provides: a method for producing ...  
WO/2016/111381A1
Provided is a production method of a thiazole derivative represented by the formula (I), which has an adenosine A2A receptor antagonistic action and is useful as a therapeutic agent for, for example, Parkinson's disease, sleep disorder, ...  
WO/2016/110822A1
The invention relates to a novel creatine derivative, the carboxylic biacyl creatine derivative of formula (I) and pharmaceutically acceptable salts thereof, methods of synthesis and the use thereof in the treatment of pathologies due to...  
WO/2016/110768A1
Pharmaceutical composition for the treatment of proteinopathies comprising products which are able to stimulate growth or inhibition of at least one of Odoribacter, Oscillospira, Dehalobacterium, Alistipes, Parabacteroides, Lactobacillus...  
WO/2016/109880A1
The invention provides lipid A mimics in which one or both of the sugar residues of a natural lipid A disaccharide backbone has been replaced with an aromatic group. These lipid A mimics may further differ from a natural lipid A molecule...  
WO/2016/110160A1
Provided are methods of treating brain ischemia or hypoxia by using an inhibitor of cysteine-glutamate transporter. The inhibitor includes sorafenib and a derivative thereof, regorafenib, erastin and sulfasalazine. The inhibitor can effe...  
WO/2016/112263A1
There is described a pharmaceutical combination comprising oxybutynin or a pharmaceutically acceptable addition salt thereof, in a transdermal therapeutic system, and an acetylcholinesterase inhibitor, useful for safely treating hypochol...  
WO/2016/109531A1
This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Canna...  
WO/2016/107227A1
Disclosed are a pyrrole amide compound as represented in formula I, polymorphs thereof, or pharmaceutically acceptable salts, hydrates, or solvate compounds. The present invention has good deacetylase inhibitory activity. Additionally, t...  
WO/2016/107540A1
Disclosed are a Chinese medicinal composition for preventing or treating cardiovascular and cerebrovascular diseases and/or dementia, and a preparation method and use thereof. The composition is prepared from the following medical raw ma...  
WO/2016/109624A1
Novel treatment methods of controlling cell hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis or cardiac disorder are disclosed herein. Novel pharmaceutical compositions comprising adenosin...  
WO/2016/107579A1
The present application provides a preparation and application of flavonol as a brain-targeting synergist. The flavonol is selected from kaempferide, rutin, troxerutin, myricetin, hesperidin and derivatives thereof. The flavonol is capab...  
WO/2016/107544A1
An intermediate compound shown in formula I for preparing a pyrrole amide compound. The pyrrole amide compound has a good histone deacetylase inhibitory activity. The specific definition of the groups in formula I is shown in the descrip...  
WO/2016/107865A1
This invention relates to compounds of formula (I), their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevent...  
WO/2016/107541A1
Disclosed are a pyrrole amide compound as represented in formula I, or pharmaceutically acceptable salts, polymorphs, hydrates, or solvate compounds. R1 is chosen from hydrogen, hydroxyl, the cyano group, halogen, carboxyl, etc. R2 and R...  
WO/2016/107850A1
The invention relates to a method for obtaining a superoxide dismutase (SOD)-concentrated protein extract having a specific activity of at least 700 UI/mg protein, said method comprising a single step of extraction from a plant selected ...  
WO/2016/106760A1
Disclosed are a trifluoroacethydrazide compound as well as preparation and application thereof. The compound has a structure represented by general formula (I). The compound has multiple mechanisms of action, comprising inhibition of glu...  
WO/2016/109480A8
The invention relates to pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one and imidazo[5,1-f][1,2,4]triazin-4(3H)-one derivatives as inhibitors of the ubiquitin-specific protease 7 (USP7) useful in the treatment of cancers, neurodegenerative diseas...  
WO/2016/109480A1
The invention relates to pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one and imidazo[5,1-f][1,2,4]triazin-4(3H)-one derivatives as inhibitors of the ubiquitin-specific protease 7 (USP7) useful in the treatment of cancers, neurodegenerative diseas...  
WO/2016/106626A1
A Bruton's Tyrosine Kinase (Btk) inhibitor compounds of Formula (I), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use of Btk inhibito...  
WO/2016/106625A1
Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and their use in therapy. In particular, the use ...  
WO/2016/102706A1
The invention relates to a compound of general formula (I) (in configuration Z or E) and to pro-pheromonal compositions and formulations comprising said compound, in addition to the uses thereof for soothing purposes for non-human mammal...  
WO/2016/103450A1
The present invention addresses the problem of providing an inhibitor which has excellent inhibitory activity on a p21-activated kinase. The present invention, which has solved the above-mentioned problem, is a p21-activated kinase 1 inh...  
WO/2016/106284A3
The invention describes membrane permeable creatine prodrugs, pharmaceutical compositions comprising membrane permeable creatine prodrugs, and methods of treating diseases such as ischemia, heart failure, neurodegenerative disorders and ...  
WO/2016/103262A2
The present invention provides solid crystalline forms of apomorphine free base or a hydrate, solvate, or co-crystals thereof. Such crystalline forms may be advantageous over amorphous forms of apomorphine, e.g., amorphous salt forms suc...  

Matches 401 - 450 out of 118,932